Drug Trial Radar · NCT00064428
OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction
Last checked: Nov 20, 2026Latest source record: Sep 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,092
Actual
Start
Aug 2003
Primary completion
Feb 2006
Study completion Feb 2006
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Oct 17, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double blindcontrolled, parallel group, multi-center, multinational study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction) randomized within 24 hours of the onset of symptoms.
Conditions
- Thromboembolism
Interventions
fondaparinux - UFH not indicatedDrug
2.5mg od, sc (1st dose IV) x 8 days or discharge
Control - UFH not indicatedOther
Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
Fondaparinux - UFH indicatedDrug
2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion
Control - UFHDrug
UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
Primary outcomes
What the sponsor says the trial is designed to measure.
- Death or recurrent myocardial infarctionTime frame: up to day 30
- Severe hemorrhageTime frame: up to Day 9
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.